CDKN2B and neoplasm: On this point, Xia et al., reported the strength of CDKN2B as a tumor suppressor by inhibiting cell cycle and glycolysis [78] and Zhang and his collaborators correlated the overexpression of CDKN2B with apoptosis in hepatocellular carcinoma cells treated with Veramapil + Doxorubicine [79].